This post was originally published on this site
Total revenue at the U.S. biotech group came in at $344 million over the three months ended on June 30, a 93% drop from the $4.75 billion registered in the corresponding period last year. But the figure was higher than Bloomberg estimates of $321.8 million.
Shares in Moderna rose in premarket trading on Thursday.
This is a breaking story. Please check back later for updates.
